Emergent BioSolutions to Release Second Quarter 2015 Financial Results and Conduct a Conference Call on August 6, 2015
GAITHERSBURG, Md., July 23, 2015 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, August 6, 2015 at 8:00 am (Eastern Time) to discuss...
Emergent BioSolutions Awarded $19.7 Million BARDA Contract to Develop and Manufacture Ebola Monoclonal Antibodies
Emergent BioSolutions (NYSE:EBS) today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) valued at $19.7 million to develop and...
Emergent BioSolutions Signs Long-Term Manufacturing Agreement With Prometic Life Sciences
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed a strategic long-term manufacturing agreement with ProMetic Life Sciences Inc. This agreement provides ProMetic access to...
Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 21, 2015 at 9:00 AM Eastern; Webcast Will be Available
Emergent BioSolutions Inc. (NYSE:EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 21, 2015 beginning at 9:00 AM Eastern at the Hilton Washington DC North, 620...
Oxford University, GSK, and Emergent BioSolutions Announce Initiation of a Prime Boost Study of Ebola Vaccine Candidates
A new phase 1 study has begun at the University of Oxford that will investigate the use of a modified vaccinia Ankara (MVA) Ebola Zaire vaccine candidate (MVA EBOZ) as a prime-boost to GSK's Chimp...
Emergent BioSolutions Reports First Quarter 2015 Financial Results
Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter ended March 31,...
Emergent BioSolutions Expands Commercial Product Portfolio With FDA Approval of IXINITY, a Recombinant Factor IX Treatment for Hemophilia B
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved IXINITY® [coagulation factor IX (recombinant)], an intravenous recombinant human...
Emergent BioSolutions to Participate in May and June 2015 Investor Conferences
Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company's senior management team will participate in the following investor conferences in May and June...
Emergent BioSolutions Completes Investigation and Resumes BioThrax Manufacturing Activities; Re-Affirms Previous Full-Year 2015 Financial Outlook
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has resumed full manufacturing operations of BioThrax® (Anthrax Vaccine Adsorbed) after completing its internal manufacturing...
Emergent BioSolutions Receives FDA Approval of Anthrasil, Its Anthrax Immune Globulin, for Use in the Treatment of Inhalational Anthrax
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved Anthrasil™ [Anthrax Immune Globulin Intravenous (Human)], also known as AIGIV,...
Emergent BioSolutions Awarded $31 Million Contract for Advanced Development of NuThrax, a Next Generation Anthrax Vaccine
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of NuThraxTM...
Emergent BioSolutions Signs Agreements With Oxford University, GlaxoSmithKline, and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate
Emergent has completed proof-of concept manufacturing of an MVA Ebola Zaire vaccine candidate anticipated for use in a Phase 1 clinical study in the UK 200L scale production leverages...